Researchers at the University of California, Davis have developed a method to produce haploid progeny plants from transgenic and wild-type plants that only carry chromosomes from the wild-type gamete.

UCLA researchers have developed a novel scanning and analysis method for breathing motion-correlated CT that can provide breathing motion-artifacts free images for subsequent use in biomechanical modeling for COPD diagnosis and radiation therapy treatment planning.

A method to implement high-conductivity nanometer-scale doped-multilayer-graphene (DMG) interconnects that are compatible with high-volume manufacturing of integrated circuits (ICs).

Researchers at the University of California, Davis have developed a solar radiation assessment method for grapes that uses a flavonol profile. This method can be done using either HPLC or through the computer processing of the absorption spectra of a purified flavonol extract via a purification kit.

Maintaining secure networks is critical for large and high-value institutions, but providing technical staff with remote direct access to sensitive systems and real-time operational data can be vital to protecting value. For example, UC San Diego maintains highly-secure networks, yet there is a need to provide monitoring for freezer systems that contain priceless samples and materials that are often irreplaceable

Researchers at the University of California, Davis have developed a surface sanitation validation system that utilizes a non-living edible surrogate to potentially help determine food processing efficacy.

Method using renewable monomers to easily make decomposable and recyclable epoxy thermosets with similar properties as thermosets made with BPA.

Vedolizumab (VDZ) is an effective therapy for the management of patients with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD) who have failed conventional therapy with aminosalicylates, corticosteroids, and thiopurines, as well as biologic therapy with tumor necrosis factor (TNF) antagonists. Several studies have identified potential predictors of treatment outcomes; however, the optimal approach to integrating predictors into routine practice is uncertain.No prior decision support tools exist to predict VDZ drug exposure in UC and CD and link this back to differences in effectiveness or response to VDZ dose escalation. By having a tool that can predict at baseline prior to start of therapy whether VDZ will be effective and what a patients drug exposure profile will be with VDZ, the provider can 1) determine if VDZ is an appropriate therapy to begin, 2) proactively monitor those patients deemed high risk for treatment failure with VDZ, and 3) proactively measure drug concentrations for VDZ to then increase the dose or the interval at which VDZ is administered to improve outcomes.